TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7783314

Group type: EXPERIMENTAL
Intervention: Tazobactam/Piperacillin (TAZ/PIPC)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Piperacillin (PIPC)
Number of subjects: 173
Study: 2194334

Group type: EXPERIMENTAL
Intervention: Allomin-lactulose 2%
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Allomin-lactulose 4%
Number of subjects: 220
Study: 389825

Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg t.i.d. for ten days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin 2 g t.i.d. for ten days
Number of subjects: 100
Study: 31853594

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 33
Study: 31305347

Group type: EXPERIMENTAL
Intervention: Titanium curette treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Carbon fiber reinforced plastic curette treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling with carbon fiber tip treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Air polishing with glycine powder
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group without any treatment
Number of subjects: 5
Study: 28533209

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of allogeneic human cardiac stem cells
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 55
Study: 26179203

Group type: EXPERIMENTAL
Intervention: Production workers with greater barriers to cessation
Number of subjects: 713

Group type: COMPARATOR
Intervention: Managers
Number of subjects: 713
Study: 23763989

Group type: EXPERIMENTAL
Intervention: Abnormal median CMAP amplitudes
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Abnormal SNAP amplitude
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Abnormal FMCV
Number of subjects: 229
Study: 21542016

Group type: EXPERIMENTAL
Intervention: Pardoprunox 6 mg/day
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Pardoprunox 12 mg/day
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Pardoprunox flexible-dose 12-42 mg/day
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Pramipexole 1.5-4.5 mg/day
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Pardoprunox (all doses)
Number of subjects: 696
Study: 18647614

Group type: EXPERIMENTAL
Intervention: Morphosemantic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphophonological treatment
Number of subjects: 0
Study: 17276965

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 43
Study: 12974569

Group type: EXPERIMENTAL
Intervention: Concurrent reproduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed reproduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both concurrent and delayed conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory for a seen model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful reproduction
Number of subjects: 0
Study: 10900819

Group type: EXPERIMENTAL
Intervention: Fair procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfair procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outcome expectancies
Number of subjects: 0
Study: 8730113

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CyA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-penicillamine (D-Pen)
Number of subjects: 0
Study: 1329698

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose cyclosporine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Corticosteroids and cyclosporine (combination therapy)
Number of subjects: 6
Study: 6149592

Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine agonist, apomorphine (AP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine receptor blockade
Number of subjects: 0
Study: 31075323

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet (MED/LC + 28 g walnuts/day)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 278
Study: 28703422

Group type: EXPERIMENTAL
Intervention: Interdental brush with a handle (HB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Newly invented interdental cleaning device (NB)
Number of subjects: 40
Study: 27045811

Group type: EXPERIMENTAL
Intervention: Daily boost of 0.5 Gy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Weekly boost of 2 Gy
Number of subjects: 400
Study: 26090731

Group type: EXPERIMENTAL
Intervention: Standard radiation dose
Number of subjects: 278

Group type: COMPARATOR
Intervention: 37% reduced radiation dose
Number of subjects: 278
Study: 23361170

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 21491486

Group type: EXPERIMENTAL
Intervention: 60 Hz vibration intervention
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 90 Hz vibration intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 65
Study: 19418387

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnet stimulation
Number of subjects: 0
Study: 17035145

Group type: EXPERIMENTAL
Intervention: Home remediation aimed at moisture sources including household repairs, action plan, education, and individualized problem solving.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group received only home cleaning information.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Home remediation group (as treated).
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Home remediation group (intent to treat).
Number of subjects: 62
Study: 12623166

Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 30

Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 30
Study: 10672454

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study: 9190510

Group type: EXPERIMENTAL
Intervention: Rehabilitation plus relaxation therapy (six weekly sessions of breathing and relaxation instruction)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Cardiac rehabilitation alone
Number of subjects: 156
Study: 8109770

Group type: EXPERIMENTAL
Intervention: Ketorolac infusion (30 mg IM premedication + 2 mg/h continuous infusion)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (NaCl 0.9% IM bolus + 2 mL/h saline infusion)
Number of subjects: 95
Study: 2470245

Group type: EXPERIMENTAL
Intervention: FUra + LV* (high dose 200 mg/m2)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: FUra + LV* (low dose 20 mg/m2)
Number of subjects: 212

Group type: COMPARATOR
Intervention: FUra (single agent)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: FUra + LV* (both doses)
Number of subjects: 212
Study: 30302936

Group type: EXPERIMENTAL
Intervention: AZL‐M/CLD 40/25 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: AZL‐M/CLD 40/12.5 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: AZL‐M 40 mg
Number of subjects: 3
Study: 28818881

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control (GRIPHON overall population)
Number of subjects: 334
Study: 26330059

Group type: EXPERIMENTAL
Intervention: e‐learning program
Number of subjects: 161

Group type: COMPARATOR
Intervention: peer‐reviewed articles
Number of subjects: 161
Study: 24576271

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based rehabilitation program with monthly motivational consultation from 6 to 12 months
Number of subjects: 178

Group type: COMPARATOR
Intervention: Oral drug treatment
Number of subjects: 178
Study: 23421309

Group type: EXPERIMENTAL
Intervention: Nicotine-containing snus
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine-free snus
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucrose solution (control)
Number of subjects: 10
Study: 20923610

Group type: EXPERIMENTAL
Intervention: AS03(B) adjuvanted split-virion H1N1 vaccine
Number of subjects: 937

Group type: COMPARATOR
Intervention: Non-adjuvanted whole-virion H1N1 vaccine
Number of subjects: 937
Study: 19030637

Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 15840110

Group type: EXPERIMENTAL
Intervention: 2.2% sirolimus for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8% sirolimus for an additional 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 12420578

Group type: EXPERIMENTAL
Intervention: TPH composite resin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fuji II
Number of subjects: 4
Study: 10333932

Group type: EXPERIMENTAL
Intervention: Nutrient-fortified prepared meal plan
Number of subjects: 202

Group type: COMPARATOR
Intervention: Self-selected exchange-list diet
Number of subjects: 202
Study: 9183320

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) formula
Number of subjects: 24

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) formula
Number of subjects: 24
Study: 8245328

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (recombinant tissue-type plasminogen activator, urokinase, or a combination)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 348
Study: 3802956

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant interferon-alpha-2a (1.5 X 10(6) U daily for one week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-dose recombinant interferon-alpha-2a (18 X 10(6) U daily for one week)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-dose group switched to high-dose (18 X 10(6) U daily for another 7 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-dose group switched to low-dose (3 X 10(6) U daily for another 7 days)
Number of subjects: 14
Study: 31870450

Group type: EXPERIMENTAL
Intervention: Patchouli alcohol (PA) administered intranasally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0
Study: 29361441

Group type: EXPERIMENTAL
Intervention: Active stimulation (left tragus)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control stimulation (earlobe)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Active vs. Control (tragus stimulation)
Number of subjects: 17
Study: 26956655

Group type: EXPERIMENTAL
Intervention: Promotion goal (valued behavior promotion)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Unpleasant symptom promotion
Number of subjects: 123

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 123

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 123
Study: 25059460

Group type: EXPERIMENTAL
Intervention: Strong stimulation acupuncture
Number of subjects: 140

Group type: COMPARATOR
Intervention: Weak stimulation acupuncture (sham)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 140
Study: 23187648

Group type: EXPERIMENTAL
Intervention: Losartan treatment in patients with HFrEF
Number of subjects: 0
Study: 20008423

Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 6635

Group type: COMPARATOR
Intervention: Palivizumab
Number of subjects: 6635
Study: 18418131

Group type: EXPERIMENTAL
Intervention: Single-level artificial cervical disc (Bryan Cervical Disc prosthesis)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single-level fusion with allograft and anterior cervical plate (Atlantis anterior cervical plate)
Number of subjects: 22
Study: 16029268

Group type: EXPERIMENTAL
Intervention: Clariflex (silicone) lens
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Akreos Fit (hydrophilic acrylic) lens
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: AR40e (hydrophobic acrylic) lens
Number of subjects: 34
Study: 11814278

Group type: EXPERIMENTAL
Intervention: House-dust mite avoidance measures (encasement of mattresses, pillows, and duvets; hot-water washing of bedding)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Usual care from family physician (Control)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Removal of cats (in intervention families)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group (families who did not remove cats)
Number of subjects: 545
Study: 10523477

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 90 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS mean dose of 52.3 mg/day during one-year open label phase
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 8748432

Group type: EXPERIMENTAL
Intervention: CI-988 (300 mg/day, thrice daily)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CI-988
Number of subjects: 88
Study: 8173699

Group type: EXPERIMENTAL
Intervention: cilazapril on low salt intake
Number of subjects: 9

Group type: COMPARATOR
Intervention: cilazapril on high salt intake
Number of subjects: 9

Group type: COMPARATOR
Intervention: dihydralazine on low salt intake
Number of subjects: 9

Group type: COMPARATOR
Intervention: dihydralazine on high salt intake
Number of subjects: 9
Study: 3885441

Group type: EXPERIMENTAL
Intervention: Oral analgesia with paracetamol 320 mg, caffeine 32 mg, codeine phosphate 8 mg, and meprobamate 150 mg (Stopayne)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral analgesia with dipyrone 500 mg, pitofenone hydrochloride 5 mg, and fenpiverinium bromide 0.1 mg (Baralgan HS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral administration of pethidine 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral administration of dipyrone 2500 mg
Number of subjects: 0
Study: 31887803

Group type: EXPERIMENTAL
Intervention: Hyaluronidase injection (5000 IU)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (normal saline injection)
Number of subjects: 148
Study: 29795544

Group type: EXPERIMENTAL
Intervention: Active stimulation (manual pressure on the lateral heel)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control stimulation (manual pressure on the lateral ankle)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 28
Study: 27591953

Group type: EXPERIMENTAL
Intervention: Low-dose vaccine (7.5 mcg HA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose vaccine (15 mcg HA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 24289244

Group type: EXPERIMENTAL
Intervention: 1064-nm Q-switched Nd:YAG laser plus chemical peeling with Jessner's solution
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1064-nm Q-switched Nd:YAG laser plus chemical peeling with placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 52
Study: 22071673

Group type: COMPARATOR
Intervention: Corneal sensitivity measurement in PED and corneal erosion groups
Number of subjects: 99

Group type: COMPARATOR
Intervention: Schirmer test values in SPK group
Number of subjects: 99
Study: 19892995

Group type: EXPERIMENTAL
Intervention: Lowest quartile of pessimism (low pessimism level)
Number of subjects: 23216
Study: 18198203

Group type: EXPERIMENTAL
Intervention: Nurse-led secondary prevention clinics
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1343
Study: 16096831

Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg once daily (q.d.)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Darifenacin 30 mg once daily (q.d.)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg three times daily (t.i.d.)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 12466341

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 10603716

Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection using LAM antibody
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection using PGL-1, 30 kD and 65 kD antibodies
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immunohistochemical detection in bacteriologically negative tissue
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection of protein antigens
Number of subjects: 13
Study: 7794078

Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (operated patients)
Number of subjects: 136
Study: 2041036

Group type: EXPERIMENTAL
Intervention: felodipine 5 mg ER formulation
Number of subjects: 102

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study: 6992910

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene) 200 mg t.d.s. for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene)
Number of subjects: 0
Study: 31109190

Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Number of subjects: 734

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 734
Study: 28728583

Group type: EXPERIMENTAL
Intervention: Financial incentives up to £400 for smoking cessation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 93
Study: 26107684

Group type: COMPARATOR
Intervention: Calcium Carbonate Chewable D3 tablet (thrice daily)
Number of subjects: 198

Group type: COMPARATOR
Intervention: MESE exercise (thrice daily, 7 repetitions per time for 12 months)
Number of subjects: 198

Group type: COMPARATOR
Intervention: MESE exercise + Calcium Carbonate Chewable D3 tablet (thrice daily for 12 months)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: MESE exercise
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: MESE exercise + Calcium Carbonate Chewable D3 tablet
Number of subjects: 198
Study: 24565122

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide (50% O2-N2O mixture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (50% O-air mixture)
Number of subjects: 40
Study: 21040197

Group type: EXPERIMENTAL
Intervention: LFD fluconazole prophylaxis (twice a week for up to 6 weeks)
Number of subjects: 244

Group type: COMPARATOR
Intervention: FD fluconazole prophylaxis (every 72 h for first 2 weeks, every 48 h for next 2 weeks and every 24 h for the final 2 weeks)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: LFD fluconazole prophylaxis
Number of subjects: 244
Study: 19403550

Group type: EXPERIMENTAL
Intervention: Perception exercise group (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study: 17466699

Group type: EXPERIMENTAL
Intervention: Cefazolin administered 15-60 minutes prior to skin incision
Number of subjects: 357

Group type: COMPARATOR
Intervention: Cefazolin administered at the time of cord clamping
Number of subjects: 357
Study: 15478524

Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Midodrine 5 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 11566628

Group type: EXPERIMENTAL
Intervention: MDC and TARC mRNA expression in inflamed mucosa from CD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDC production from PBMC in CD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDC and TARC mRNA expression in UC patients
Number of subjects: 0
Study: 10021952

Group type: COMPARATOR
Intervention: Epidural F (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 saline followed by 2 micrograms.ml‐1 fentanyl infusion)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Epidural F‐B (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 bupivacaine 0.25% followed by 2 micrograms.ml‐1 fentanyl infusion in bupivacaine 0.125%)
Number of subjects: 42
Study: 7932133

Group type: EXPERIMENTAL
Intervention: STAAR Elastimide three‐piece foldable intraocular lens inserted through a 4.0 mm incision
Number of subjects: 112

Group type: COMPARATOR
Intervention: STAAR poly(methyl methacrylate) (PMMA) lens inserted through a 7.0 mm incision
Number of subjects: 112
Study: 2851506

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ORG OD14
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 29645341

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg once daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28253893

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 25430779

Group type: EXPERIMENTAL
Intervention: 50 mg GSK561679 (low-GSK)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 400 mg GSK561679 (high-GSK)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 23701526

Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 114
Study: 20089518

Group type: EXPERIMENTAL
Intervention: Functional MBL deficiency (serum MBL levels of or below 100 ng/mL)
Number of subjects: 890

Group type: COMPARATOR
Intervention: MBL levels >100 ng/mL
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Functional MBL deficiency
Number of subjects: 890
Study: 18935806

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 0